Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06587828 · ClinicalTrials.gov registry record
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
A clinical trial of Multiple Sclerosis and Ulcerative Colitis, sponsored by TScan Therapeutics.
- Recruiting
- Registry status
- 300
- Enrollment target
- 12
- Study locations
NCT06587828: Recruiting study of Multiple Sclerosis and Ulcerative Colitis, sponsored by TScan Therapeutics.
NCT06587828 is a study of Multiple Sclerosis and Ulcerative Colitis that is actively recruiting participants, run by TScan Therapeutics. The registered enrollment target is 300 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (49% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06587828, a study of Multiple Sclerosis and Ulcerative Colitis, is actively recruiting participants, sponsored by TScan Therapeutics.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 12
- Study locations
Study Summary
The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation. These tissues contain both cytotoxic and helper T cells that are driving their disease, and these T cells are being guided by TCRs that recognize tissue-specific targets. By collecting tissue when a patient has active inflammation, it is possible to determine which T cells are activated and undergoing clonal expansion in the patient's diseased organ. TScan has developed a genome-wide, high-throughput technology to determine the natural, physiological target of any TCR (Kula, 2019). The goal of this study is to isolate T cells from inflamed tissues and matched blood samples and/or matched normal tissues (for patients with inflammatory bowel diseases). T cell clones that are expanded in diseased tissues relative to blood or normal tissues will be selected and the targets of their TCRs will be defined using TScan's genome-wide, high-throughput target ID technology. The goal of this study is to discover a collection of peptide targets, along with their associated TCRs to be developed as new tolerogenic therapies for patients with autoimmune diseases.
Conditions Studied
Interventions
- PROCEDURE Companion blood samples with procedure
Study Locations (12)
Rhode Island
- Nexus Research - Cranston
- Nexus Research - Cranston
- RI Rheumatology - Cranston
California
- Knowledge Research Center - Orange
- Cura Clinical Research - Sherman Oaks
Illinois
- Arnold Arthritis & Rheumatology - Skokie
Kentucky
- University of Kentucky Research Foundation - Lexington
Massachusetts
- Massachusetts Eye Research and Surgery Institution (MERSI) - Waltham
Pennsylvania
- Susquehanna Research Group - Harrisburg
South Carolina
- Palmetto Gastroenterology Clinical Research, LLC - Summerville
Texas
- Novel Research - Bellaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2027-01 |
What NCT06587828 shows while recruiting
NCT06587828 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (49% lower).
The record links to 9 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Companion blood samples with procedure is the first listed.
NCT06587828 lists 12 locations in 9 states (Rhode Island, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT06587828 about?
NCT06587828 is a clinical study titled "A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease". The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation. These tissues contain both cytotoxic and helper T cells that are driving their disease, and these T cells are b...
What is the current status of trial NCT06587828?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2023-01-03. Estimated completion is 2027-01.
What conditions does trial NCT06587828 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Ulcerative Colitis, Crohn's Disease, Autoimmune Diseases, Celiac Disease.
What interventions are being tested in trial NCT06587828?
The interventions under investigation include: Companion blood samples with procedure (PROCEDURE).
Who is sponsoring clinical trial NCT06587828?
This trial is sponsored by TScan Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06587828 being conducted?
This trial has 12 study locations across California, Illinois, Kentucky, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06587828's enrollment target sits among peer trials
300 56th of 315 higher than 256 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI